Souhaitez-vous accéder aux communiqués récents ?

Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of...

Austin, TX, USA, July 22, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Plant Tissue Culture Market Size, Trends and Insights By Crop Type (Banana...

WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...

60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.

60 Degrees to seek FDA MUMS designation for tafenoquine in canine babesiosis, supported by 3 studies showing efficacy and safety in treating babesiosis.

Salarius Pharmaceuticals granted additional extention to regain Nasdaq compliance

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy...